Citigroup Inc Castle Biosciences Inc Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Citigroup Inc holds 6,654 shares of CSTL stock, worth $141,464. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,654

Previous 5,585 19.14%

Holding current value

$141,464

Previous $120,000 22.5%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$18.06 - $25.3 $19,306 - $27,045	1,069 Added 19.14%	6,654 $147,000
Q4 2023 Feb 09, 2024	BUY	$12.19 - $22.43 $34,802 - $64,037	2,855 Added 104.58%	5,585 $120,000
Q3 2023 Nov 09, 2023	SELL	$13.28 - $20.3 $112,123 - $171,392	-8,443 Reduced 75.57%	2,730 $46,000
Q2 2023 Aug 10, 2023	BUY	$11.66 - $26.0 $98,258 - $219,102	8,427 Added 306.88%	11,173 $153,000
Q1 2023 May 11, 2023	SELL	$19.47 - $28.49 $14,135 - $20,683	-726 Reduced 20.91%	2,746 $62,000

Q4 2022 Feb 09, 2023	SELL	$18.08 - $30.0 $1.51 Million - $2.51 Million	-83,501 Reduced 96.01%	3,472 $81,000
Q3 2022 Nov 10, 2022	SELL	$22.51 - $34.32 $1.03 Million - $1.58 Million	-45,964 Reduced 34.58%	86,973 $2.27 Million
Q2 2022 Aug 10, 2022	BUY	$16.0 - $45.99 $1.99 Million - $5.72 Million	124,294 Added 1438.09%	132,937 $2.92 Million
Q1 2022 May 12, 2022	SELL	$33.17 - $46.98 $196,499 - $278,309	-5,924 Reduced 40.67%	8,643 $388,000
Q4 2021 Feb 10, 2022	SELL	$39.06 - $67.58 $41,442 - $71,702	-1,061 Reduced 6.79%	14,567 $624,000
Q3 2021 Nov 10, 2021	BUY	$60.13 - $77.6 $939,711 - $1.21 Million	15,628 New	15,628 $1.04 Million

Others Institutions Holding CSTL

# of Institutions

162

Shares Held

25.3M

Call Options Held

82.2K

Put Options Held

150K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $559M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account